D-2570
Sponsors
InventisBio Co., Ltd
Conditions
Active Systemic Lupus ErythematosusHealthyHealthy Adult ParticipantsHealthy VolunteerHepatic Impairment (HI)Moderately to Severely Active Ulcerative ColitisPlaque PsoriasisPsA (Psoriatic Arthritis)
Phase 1
Healthy Volunteer Study
Active, not recruitingNCT07270783
Start: 2025-12-04End: 2026-09-01Target: 36Updated: 2026-07-14
Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
CompletedNCT07275775
Start: 2024-08-13End: 2025-06-23Updated: 2025-12-10
The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.
Not yet recruitingNCT07715175
Start: 2026-08-09End: 2026-11-21Target: 40Updated: 2026-07-23
A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function
RecruitingNCT07715149
Start: 2026-07-14End: 2026-11-30Target: 24Updated: 2026-07-20
Phase 2
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
CompletedNCT06278350
Start: 2024-01-31End: 2024-11-01Updated: 2025-12-09
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
Active, not recruitingNCT07035041
Start: 2025-05-22End: 2026-12-31Target: 120Updated: 2026-07-17
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
RecruitingNCT07311200
Start: 2026-02-12End: 2028-12-31Target: 120Updated: 2026-04-24
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
RecruitingNCT07315061
Start: 2026-01-16End: 2028-08-06Target: 222Updated: 2026-04-22